HONG KONG – A Chinese study has shown for the first time that the powerful antidepressant effects of ketamine are due to blockade of rapid neuronal firing in the brain's lateral habenula (LHb) region. Such blockade was found to disinhibit reward centers and relieve depressive symptoms rapidly in animal models. Read More
HYDERABAD, India – Companies are increasingly willing to invest in biosimilar development and manufacturing in India, despite a spate of regulatory hurdles and a shortage of capital that remain visible. Read More
SINGAPORE – From faster approval processes and shifts in manufacturing processes to changing stakeholder roles and the rise of preventive med tech, discussions at the recent Phar-East 2018 meeting underscored the major currents of change flowing through Asia's biotech and med-tech industries. Read More
HYDERABAD, India – Indian pharmaceutical companies are taking baby steps toward a greater collaboration with digital tech firms and data analytics, but they may not be moving fast enough. Delegates at the BioAsia 2018 conference said such collaborations should speed up to tap into that significant innovation potential. Read More
SINGAPORE – China, India, Japan and Korea are prominent Asian players in the global biotech space, while Singapore has emerged as an increasingly notable global contributor, but there remains a gap in terms of contributions from other parts of Southeast Asia. A common theme emerging this week at the Phar-East Pharma and Biotech Festival (formerly known as the BioPharma Asia Convention) focused on ways to foster biotech and bioentrepreneurship in the region. Read More
HONG KONG – Singapore's Tessa Therapeutics Pte. Ltd. is more than halfway through the recruitment for what it said is the world's largest phase III T-cell immunotherapy trial for any cancer indication. If all goes well, the company is expecting a product launch in two years. Read More
Moleac Pte. Ltd., of Singapore, said the FDA has approved an investigational new drug application for a phase I study of MLC-1501, an herbal concoction intended for use in post-stroke recovery treatment. Read More
